Biosimilar Newsletter Archive

1. 01.26.23 -- Make The Service Agreement Work For You And Your CDMO 1/26/2023
   01/26/23 Biosimilar Development Newsletter
2. 01.20.23 -- De-Risking Combination Product Development For Biosimilars 1/20/2023

   01/20/23 Biosimilar Development Newsletter

3. 01.19.23 -- 4 Key Takeaways For Combination Products As We Move Into 2023 1/19/2023
   01/19/23 Biosimilar Development Newsletter
4. 01.12.23 -- FDA Accepts Stelara Biosimilar BLA For Review 1/12/2023
   01/12/23 Biosimilar Development Newsletter
5. 01.05.23 -- Where Do We Stand On Adopting Continuous Manufacturing For Biologics? 1/5/2023
   01/05/23 Biosimilar Development Newsletter
6. 12.22.22 -- FDA Accepts Biogen BLA For Biosimilar Actemra 12/22/2022
   12/22/22 Biosimilar Development Newsletter
7. 12.15.22 -- ACMA Develops Board-Certified Biologics & Biosimilars Specialist Certification 12/15/2022
   12/15/22 Biosimilar Development Newsletter
8. 12.12.22 -- Don't Miss 6 Key Topics That Changed Biopharma Testing In 2022 12/12/2022

   12/12/22 Biosimilar Development Newsletter

9. 12.08.22 -- Biocon Completes Acquisition Of Viatris Biosimilar Business 12/8/2022
   12/08/22 Biosimilar Development Newsletter
10. 12.07.22 -- Top 2022 Articles On Process Development 12/7/2022

    12/07/22 Biosimilar Development Newsletter